Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent that protects its lead AMPAKINE® molecule, CX1739. The patent, entitled "Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses," specifically covers CX1739, Cortex's third generation Low Impact AMPAKINE compound that is currently in Phase II clinical development. Along with CX1739, the allowed patent covers approximately 80 additional structures that will have patent protection into 2028.
“Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses”
"We are most appreciative to our Senior Director of Medicinal Chemistry, Leslie Street, Ph.D., and our Director of Chemistry, Rudolf Mueller, Ph.D., who are co-inventors on the allowed patent," said Dr. Mark A. Varney, Cortex President and CEO.
"This patent will make Cortex's low impact AMPAKINE platform more attractive for partnering due to the superiority of these latest AMPAKINE compounds in potency, safety and patent life over earlier low impact AMPAKINE compounds. With 17 years of patent life remaining on CX1739 and other compounds in this allowed patent, Cortex looks forward to developing, partnering and commercializing these new AMPAKINE compounds for the treatment of neurological and cardio-respiratory diseases, as well as psychiatric disorders, such as ADHD, depression and schizophrenia," said Dr. Varney. "Cortex's strategy has been to file patents aggressively on new inventions. This patent application has been filed broadly in major markets, and patent prosecution in these other countries continues," stated Dr Varney.
AMPAKINE compounds have previously demonstrated proof-of-concept in clinical studies in ADHD, and in the prevention of opiate-induced respiratory depression. Earlier this year, Cortex reported results from a Phase IIa sleep lab study with CX1739 in subjects with moderate to severe sleep apnea. The results from this study suggested a potential opportunity for CX1739 in the treatment of central sleep apnea, which is often seen in heart failure patients and chronic opiate users.
SOURCE Cortex Pharmaceuticals, Inc.
皮质制药公司（OTCBB：CORX）宣布，美国专利和商标局颁发的专利，保护其领导AMPAKINE ®分子，CX1739的津贴通知。该专利名为“迪取代提高谷氨酸突触反应酰胺，”具体包括CX1739，皮质的第三代低影响AMPAKINE化合物，是目前处于第二阶段临床开发。随着CX1739，允许的专利覆盖了大约80个额外的结构，到2028年将有专利保护。
“迪取代酰胺提高谷氨酸突触反应”
“我们非常感谢我们的高级总监药物化学，莱斯利街，博士，和我们的主任化学，鲁道夫米勒博士，谁是双方在允许的专利发明人，博士说：”马克答：瓦尼，皮质总裁兼CEO。
“这项专利会使大脑皮质的影响不大AMPAKINE平台的建立伙伴关系由于这些最新AMPAKINE的效力，安全性和专利的生活化合物超过同期低影响AMPAKINE化合物优势的吸引力。随着17年专利生命年CX1739和其他化合物剩余这使专利，皮质期待着发展，合作和商业化的神经系统和心肺疾病的治疗这些新AMPAKINE化合物，以及精神疾病，如多动症，抑郁症和精神分裂症，博士说：“瓦尼。 “皮质的战略，一直到文件上的新发明专利积极。这项专利申请已被广泛地提出在主要市场，而在其它国家的专利起诉继续说：”瓦尼博士指出。